BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24947313)

  • 1. Intra-arterial carboplatin as a salvage strategy in the treatment of recurrent glioblastoma multiforme.
    Fortin D; Morin PA; Belzile F; Mathieu D; Paré FM
    J Neurooncol; 2014 Sep; 119(2):397-403. PubMed ID: 24947313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy.
    Chow KL; Gobin YP; Cloughesy T; Sayre JW; Villablanca JP; Viñuela F
    AJNR Am J Neuroradiol; 2000 Mar; 21(3):471-8. PubMed ID: 10730637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma.
    Arakawa Y; Mizowaki T; Murata D; Fujimoto K; Kikuchi T; Kunieda T; Takahashi JC; Takagi Y; Miyamoto S
    Neurol Med Chir (Tokyo); 2013; 53(11):779-85. PubMed ID: 24140770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The added value of bevacizumab concomitantly administered with carboplatin versus carboplatin alone in patients with recurrent glioblastomas.
    Kaloshi G; Diamandi P; Cakani B; Brace G; Rroji A; Petrela M
    Tumori; 2015; 101(1):41-5. PubMed ID: 25702676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme.
    Chamberlain MC; Tsao-Wei DD
    Cancer; 2004 Mar; 100(6):1213-20. PubMed ID: 15022289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage therapy with single agent bendamustine for recurrent glioblastoma.
    Chamberlain MC; Johnston SK
    J Neurooncol; 2011 Dec; 105(3):523-30. PubMed ID: 21626071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ACNU-cisplatin continuous infusion chemotherapy as salvage therapy for recurrent glioblastomas: phase II study.
    Gwak HS; Youn SM; Kwon AH; Lee SH; Kim JH; Rhee CH
    J Neurooncol; 2005 Nov; 75(2):173-80. PubMed ID: 16132508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
    J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme.
    Aoki T; Mizutani T; Nojima K; Takagi T; Okumura R; Yuba Y; Ueba T; Takahashi JA; Miyatake S; Nozaki K; Taki W; Matsutani M
    J Neurosurg; 2010 Jan; 112(1):50-6. PubMed ID: 19538050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme: a phase II study.
    Brandes AA; Rigon A; Zampieri P; Ermani M; Carollo C; Altavilla G; Turazzi S; Chierichetti F; Florentino MV
    Cancer; 1998 Jan; 82(2):355-61. PubMed ID: 9445194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
    Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
    Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma.
    de Groot JF; Gilbert MR; Aldape K; Hess KR; Hanna TA; Ictech S; Groves MD; Conrad C; Colman H; Puduvalli VK; Levin V; Yung WK
    J Neurooncol; 2008 Oct; 90(1):89-97. PubMed ID: 18581057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.
    Addeo R; Caraglia M; De Santi MS; Montella L; Abbruzzese A; Parlato C; Vincenzi B; Carraturo M; Faiola V; Genovese M; Cennamo G; Del Prete S
    J Neurooncol; 2011 May; 102(3):417-24. PubMed ID: 20694830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
    Field KM; Simes J; Nowak AK; Cher L; Wheeler H; Hovey EJ; Brown CS; Barnes EH; Sawkins K; Livingstone A; Freilich R; Phal PM; Fitt G; ; Rosenthal MA
    Neuro Oncol; 2015 Nov; 17(11):1504-13. PubMed ID: 26130744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
    Reardon DA; Desjardins A; Peters KB; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Bulusu A; Threatt S; Friedman AH; Vredenburgh JJ; Friedman HS
    J Neurooncol; 2012 Mar; 107(1):155-64. PubMed ID: 21986722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.
    Gállego Pérez-Larraya J; Ducray F; Chinot O; Catry-Thomas I; Taillandier L; Guillamo JS; Campello C; Monjour A; Cartalat-Carel S; Barrie M; Huchet A; Beauchesne P; Matta M; Mokhtari K; Tanguy ML; Honnorat J; Delattre JY
    J Clin Oncol; 2011 Aug; 29(22):3050-5. PubMed ID: 21709196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.
    Clarke JL; Iwamoto FM; Sul J; Panageas K; Lassman AB; DeAngelis LM; Hormigo A; Nolan CP; Gavrilovic I; Karimi S; Abrey LE
    J Clin Oncol; 2009 Aug; 27(23):3861-7. PubMed ID: 19506159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience.
    Scoccianti S; Detti B; Sardaro A; Iannalfi A; Meattini I; Leonulli BG; Borghesi S; Martinelli F; Bordi L; Ammannati F; Biti G
    Anticancer Drugs; 2008 Jul; 19(6):613-20. PubMed ID: 18525321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme.
    Grossmann KF; Colman H; Akerley WA; Glantz M; Matsuoko Y; Beelen AP; Yu M; De Groot JF; Aiken RD; Olson JJ; Evans BA; Jensen RL
    J Neurooncol; 2012 Nov; 110(2):257-64. PubMed ID: 22932984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.